SR-9009 (Stenabolic) is a Rev-ErbA agonist studied for its effects on circadian metabolism and endurance research. Below, we compare vendors currently stocking research-grade SR-9009 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 MuscleChemBest Value |
£49.99 | In-house testing | Buy Here → | |
 Next Chem |
$71.95 (liquid solution) | Third-party COA | Auto-applied | Buy Here → |
 Chemyo |
$79.99 (10mg/ml solution) | Third-party COA | Buy Here → |
SR9009 (Stenabolic) is a synthetic REV-ERBα agonist developed by researchers at the Scripps Research Institute as a tool compound for studying circadian-rhythm biology and metabolism. Despite its bodybuilding-community nickname, it is not a SARM and does not interact with the androgen receptor.
Research-grade SR9009 is typically supplied as a liquid solution or capsules, commonly at 10mg/mL or 10mg per capsule, intended for laboratory research use only. SR9009 is noted for very poor oral bioavailability in its native form, a limitation frequently discussed in the research literature.
SR9009 activates REV-ERBα, a nuclear receptor central to the molecular circadian clock that also regulates genes involved in lipid metabolism, mitochondrial biogenesis, and inflammatory pathways — its research relevance stems primarily from chronobiology, not androgen signaling.
SR9009 was originally developed as a tool compound to probe REV-ERB's role in the molecular clock, and remains widely used in that specific area of academic chronobiology research rather than as a developed drug candidate.
Preclinical studies in mice have investigated SR9009's effects on running endurance, energy expenditure, and lipid metabolism, which is the basis for its research-community popularity, though its poor bioavailability is a frequently cited limitation of these findings translating to oral human use.
SR9009 has not advanced past preclinical animal research and has no completed human clinical trials, no established human safety data, and no FDA approval. Its very short elimination half-life and bioavailability issues are additional reasons it has not been developed further pharmaceutically.
No FDA-approved or clinically validated human dosage exists for SR9009. Doses used in mouse studies are documented in that specific preclinical literature and do not translate to a human protocol.
Compound X does not sell SR-9009 (Stenabolic) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
SR9009 research is indexed on PubMed under search terms such as "SR9009 REV-ERB agonist" and "Stenabolic circadian nuclear receptor."
New guides, vendor comparisons and compound breakdowns every week.